HHS-FDA peptide compounding policy review

Description HHS and the FDA are seeking White House review of an interim policy that would authorize nationwide compounding of certain peptide medications. Overview The FDA asked the White House to review new guidelines for compounding peptide-based medications through HHS. The interim access policy would create federal… Read more